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September 18, 2012:1117–21Figure 1 shows that the majority of the studies had a point
estimate to the right of 0. The 2-sided p value from the sign test
is 0.023. In Study 9, the treatment effect in the United States
seemed to be substantially better than outside the United States,
but in Studies 5, 12, 13, 17, and 21, the treatment effect appeared
to be substantially worse in the United States than outside of the
United States.
In the random effects meta-analysis, the estimate of the
between-trial variability was 0. The estimate of the mean log-
hazard ratio was 0.103 with a standard error of 0.035. Thus, the
approximate confidence interval is (0.031 to 0.175) and the 2-sided
p value for the test of mean zero difference is p  0.007. Because
the estimate of the between-trial variability was zero, the point
estimate and estimated standard error from the fixed effect model
are identical to those from the random effect model described.
It seems that there may be systematic differences between the
treatment effects observed in the United States and non-U.S.
regions, with the U.S.-specific treatment effect usually being
smaller. Some factors that might contribute to differences in
treatment effects between regions include differences in compli-
ance, follow-up, and concomitant medications. There are other
possible explanations, and in any particular trial the factors that
may attenuate the treatment effect may not be anticipated or even
measured. In future trials, if there is a concern that there may be a
difference in the treatment effect in the United States versus other
countries and the U.S.-specific treatment effect is of interest, there
are both issues of design and analysis to consider. An analysis could
be planned in the protocol to deal with this possible difference.
This could include formal tests for interaction or examination of
differences in baseline characteristics or background therapy be-
tween regions. Planning for a test for qualitative or quantitative
interaction is helpful in some cases, but both tests are known to
have low power when the differences are moderate, and this
situation may not be totally satisfactory for this purpose. In studies
in which a goal of the study is to confirm a global treatment effect
and a country-specific treatment effect, there should be a plan to
obtain a sufficient amount of information in the country or region
of interest, and an analysis should be pre-planned to do so.
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Letters to the Editor
Safety of Dabigatran Versus
Warfarin for Periprocedural
Anticoagulation in Patients
Undergoing Ablation for
Atrial Fibrillation
We read with interest the recent report by Lakkireddy et al. (1)
regarding periprocedural dabigatran in patients undergoing atrial
fibrillation (AF) ablation. This multicenter study noted a signifi-
cant increase in bleeding and thromboembolic complications with
essentially uninterrupted dabigatran versus uninterrupted warfarin.
Their findings emphasize the importance of fully understanding
the pharmacokinetics of pharmacologic agents, particularly anti-
coagulants, which can cause serious complications. Dabigatran
possesses several pharmacokinetic properties that are important to
safe periprocedural use. These properties predict the potential for
increased complications when used in an uninterrupted manner for
ablations.
1. There is an in vitro heparin-dabigatran interaction (2). Dab-
igatran potentiates heparin’s antithrombotic properties with
quantitatively doubled anticoagulant effect. The increased
bleeding complications noted by Lakkireddy et al. (1) suggest that
this in vitro interaction very likely occurs in vivo. This interaction
is much less apparent with rivaroxaban and apixaban (2).
2. Immediately following hip surgery, dabigatran absorption can
be both delayed and reduced (3). Thus, oral dabigatran imme-
diately after an AF ablation may not provide anticoagulation
during the immediate post-procedural period. Enoxaparin im-
mediately post-ablation will avoid this anticoagulant lapse until
oral absorption of dabigatran occurs.
3. Dabigatran has no direct antidote, so when bleeding compli-
cations occur they may be more difficult to treat than those with
warfarin.
Based on these pharmacokinetic considerations, we agree it is
not appropriate to use dabigatran in a nearly uninterrupted
manner. This does not diminish dabigatran’s utility when used in
an interrupted manner. We have reported the safety of interrupted
dabigatran in 123 patients (4) and have subsequently extended our
experience to more than 500 patients (40% of whom were on
dabigitran pre-ablation) without a single hemorrhagic or throm-
boembolic complication. As emphasized by Lakkireddy et al. (1),
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likely account for the safety and efficacy demonstrated in our series.
Heparin administration to patients in whom dabigatran has not
been fully interrupted might be expected to lead to increased
bleeding complications due to a probable drug-drug interaction
and poor absorption post-ablation might lead to increased throm-
boembolic events. The convenience of standardized oral dosing
and elimination of INR monitoring makes dabigatran and other
new oral anticoagulants attractive alternates to warfarin for AF
ablation patients.
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Reply
We appreciate the interest of Dr. Winkle and colleagues in our
recent study on the safety of periprocedural dabigatran during
atrial fibrillation (AF) ablation (1). We do concur with some of the
comments made by Dr. Winkle and colleagues and would like to
add some more information to help us all better understand this
important aspect of periprocedural anticoagulation during AF
ablation.
1. The in vitro interaction of simultaneously administered dabigatran
and heparin is well known and is probably an extension of their
pharmacodynamic properties. However, starting parenteral hepa-
rin 12 h after the last dose of dabigatran is considered reasonably
safe for bridging anticoagulation before any invasive procedure,
as supported by the safety profile in more than 600 patients who
were bridged in the Re-Ly trial, and is currently recommended
(2). The approximate mean time from the last dose of dabiga-
tran to intravenous administration of heparin was 16 h. Asmentioned in our paper, the reason for the increased bleeding
outcomes in our study may still partly be explained by the
interaction between unfractionated heparin and the residual
dabigatran effect at the time of the procedure.
2. The absorption of dabigatran after hip surgery can be delayed
and potentially reduced in a minority of patients as shown by an
increase in the time to peak and a decrease in the peak plasma
levels (3). However, the therapeutic effect of the drug can be
seen at 50% of the peak plasma level. These differences in the
plasma levels after a hip surgery are probably not clinically
significant as evidenced by multiple trials showing either
noninferiority or superiority of dabigatran when compared with
heparin in preventing venous thromboembolism in post-
operative settings (4).
3. We do recognize that the lack of a direct antidote to dabigatran
could make the management of bleeding episodes difficult.
However, the same is true for subcutaneous enoxaparin, which
was the primary anticoagulant used for bridging patients to
dabigatran by Dr. Winkle and colleagues.
There is overwhelming data to support much better outcomes
when AF ablation is done on therapeutic warfarin when compared
to the interrupted approach (5,6). When enoxaparin is used for
bridging, the bleeding complications normally occur after dis-
charge and might not be captured unless an appropriate data
collection system is in place and the thromboembolic complica-
tions (in 1% to 5% of patients) tend to be clustered in nonparox-
ysmal AF cases (5). Therefore, the lack of thromboembolic
complications in Dr. Winkle and colleagues series could be due to
either a different patient selection or a limited ablation lesion set,
which may be inadequate to achieve freedom from atrial arrhyth-
mias in the nonparoxysmal group.
We do hope that the newer anticoagulants (rivaroxaban and
apixaban), with their slightly different pharmacokinetic and phar-
macodynamic profile, would be safer than dabigatran in this
setting. Future studies evaluating these drugs as periprocedural
anticoagulants for AF ablation are urgently needed.
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